Literature DB >> 14678019

Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis.

Seon Young Nam1, Hye Seung Lee, Gyung-Ah Jung, Jimi Choi, Sung Jin Cho, Min Kyu Kim, Woo Ho Kim, Byung Lan Lee.   

Abstract

Akt/protein kinase B (PKB) plays an important role in cell survival. However, the role of Akt in the biology of gastric cancer has not been well studied. We sought to investigate the expression of Akt or phosphorylated Akt (pAkt) in human gastric carcinomas and to analyze the relationship between Akt or pAkt and the clinicopathologic parameters. The expressions of Akt and pAkt were evaluated immunohistochemically in 311 gastric carcinomas using the tissue array method. Akt expression was detected in 74% of the tumors and pAkt expression in 78%. pAkt was highly expressed in the early stage of pTNM (p=0.011). We also found an inverse association between pAkt and lymphatic invasion (p=0.01) or lymph node metastasis (p=0.008). pAkt expression was significantly correlated with a higher survival in patients with stage I carcinomas (p=0.0003). Interestingly, combined evaluation revealed that the group with pAkt-positive and lymph node-negative carcinomas showed a better prognosis than the other groups (p<0.0001). In addition, pAkt was shown to correlate positively with APC (p=0.002) and Smad4 (p<0.0001) expression. These findings suggest that pAkt expression may help to predict the clinical outcome of gastric cancer patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14678019     DOI: 10.1111/j.1600-0463.2003.apm1111205.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  32 in total

1.  Hepatic vitamin A preloading reduces colorectal cancer metastatic multiplicity in a mouse xenograft model.

Authors:  Eun Young Park; Daniel Pinali; Krista Lindley; Michelle A Lane
Journal:  Nutr Cancer       Date:  2012-05-29       Impact factor: 2.900

2.  The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway.

Authors:  Jinju Park; Young San Ko; Jiyeon Yoon; Min A Kim; Jong-Wan Park; Woo Ho Kim; Youngsun Choi; Ji Hun Kim; Younghee Cheon; Byung Lan Lee
Journal:  Gastric Cancer       Date:  2013-11-08       Impact factor: 7.370

3.  Prognostic value of co-expression of STAT3, mTOR and EGFR in gastric cancer.

Authors:  Mikito Inokuchi; Tadao Murayama; Mikiko Hayashi; Yoko Takagi; Keiji Kato; Megumu Enjoji; Kazuyuki Kojima; Jiro Kumagai; Kenichi Sugihara
Journal:  Exp Ther Med       Date:  2011-01-11       Impact factor: 2.447

4.  Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers.

Authors:  Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Marika Hayashi; Jeffrey A Meyerhardt; Andrew T Chan; Edward Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

5.  AKT and PTEN expression in human gastrointestinal carcinoid tumors.

Authors:  Susan C Pitt; Ruth Davis; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Am J Transl Res       Date:  2009-02-28       Impact factor: 4.060

Review 6.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

Authors:  Jaclyn LoPiccolo; Gideon M Blumenthal; Wendy B Bernstein; Phillip A Dennis
Journal:  Drug Resist Updat       Date:  2007-12-31       Impact factor: 18.500

7.  Phosphorylation status of Akt and caspase-9 in gastric and colorectal carcinomas.

Authors:  Akiko Sangawa; Michiko Shintani; Naoki Yamao; Shingo Kamoshida
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

8.  E-cadherin and beta-catenin expression in Epstein-Barr virus-associated gastric carcinoma and their prognostic significance.

Authors:  Chihaya Koriyama; Suminori Akiba; Tetsuhiko Itoh; Kazunobu Sueyoshi; Yoshie Minakami; Alejandro Corvalan; Suguru Yonezawa; Yoshito Eizuru
Journal:  World J Gastroenterol       Date:  2007-08-07       Impact factor: 5.742

9.  Silencing A7-nAChR levels increases the sensitivity of gastric cancer cells to ixabepilone treatment.

Authors:  Chao-Chiang Tu; Chien-Yu Huang; Wan-Li Cheng; Chin-Sheng Hung; Yu-Jia Chang; Po-Li Wei
Journal:  Tumour Biol       Date:  2016-01-20

10.  Relation between outcomes and localisation of p-mTOR expression in gastric cancer.

Authors:  T Murayama; M Inokuchi; Y Takagi; H Yamada; K Kojima; J Kumagai; T Kawano; K Sugihara
Journal:  Br J Cancer       Date:  2009-02-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.